EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Renal Protective Effect of Metformin in Type 2 Diabetes Patients

Hsi-Hao Wang, Sheng-Hsiang Lin, Shih-Yuan Hung, Yuan-Yow Chiou, Wan-Chia Hsu, Chih-Min Chang, Hung-Hsiang Liou, Min-Yu Chang, Li-Chun Ho, Ching-Fang Wu, Yi-Che Lee iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae477 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Hsi-Hao Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Hypoglycemic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Research Foundation of E-DA Hospital and National Cheng Kung University Hospital, Taiwan, Higher Education Sprout Project, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inhibiting the development and progression of diabetic kidney disease (DKD) is an important issue, but the renoprotective effect of metformin is still controversial.

Objective

To assess the renoprotective effect of metformin in patients with type 2 diabetes.

Methods

This retrospective observational multicenter cohort study included 316 693 patients with type 2 diabetes from 7 hospitals. After matching for age, gender, medical year, baseline estimated glomerular filtration rate (eGFR), urine protein (dipstick), glycated hemoglobin (HbA1c) and propensity score; a total of 13 096 metformin and 13 096 non-metformin patients were included. The main results were doubling of serum creatinine, eGFR ≤ 15 mL/min/1.73 m2 and end-stage kidney disease (ESKD).

Results

After conducting a multivariable logistic regression analysis on the variables, the metformin group was revealed to have better renal outcomes than the non-metformin group, including a lower incidence of doubling of serum creatinine (hazard ratio [HR], 0.71; 95% CI, 0.65-0.77), eGFR ≤ 15 mL/min/1.73 m2 (HR 0.61; 95% CI, 0.53-0.71), and ESKD (HR 0.55; 95% CI, 0.47-0.66). The subgroup analyses revealed a consistent renoprotective effect across patients with various renal functions. Furthermore, when considering factors such as age, sex, comorbidities, and medications in subgroup analyses, it consistently showed that the metformin group experienced a slower deterioration in renal function across nearly all patient subgroups.

Conclusion

Metformin decreased the risk of renal function deterioration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Diabetic NephropathiesHypoglycemic AgentsKidney Failure, ChronicHumansMaleFemaleRetrospective StudiesMiddle AgedGlomerular Filtration RateAgedCreatinineDisease ProgressionGlycated Hemoglobin

Stichwörter der Autor:innen

chronic kidney diseasediabetes mellitusdiabetic kidney diseaseend-stage kidney diseasekidneymetforminrenal function

Substanzen

MetforminHypoglycemic AgentsCreatinineGlycated Hemoglobin

Autor:innen und Institutionen

  • School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung 84001, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, E-DA Hospital, Kaohsiung 84001, Taiwan.
  • Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan.
  • Department of Public Health, College of Medicine, National Cheng-Kung University, Tainan 70403, Taiwan.
  • Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan.
  • Department of Pediatrics, National Cheng Kung University Hospital, Tainan 70403, Taiwan.

ORCID-Profile: Yi-Che Lee

Förderung

  • Research Foundation of E-DA Hospital and National Cheng Kung University Hospital, Taiwan
  • Higher Education Sprout Project
  • Ministry of Education
  • National Cheng Kung University

Zitieren

APA

Wang, H. H., Lin, S. H., Hung, S. Y., Chiou, Y. Y., Hsu, W. C., Chang, C. M., Liou, H. H., Chang, M. Y., Ho, L. C., Wu, C. F., & Lee, Y. C. (2025). Renal Protective Effect of Metformin in Type 2 Diabetes Patients. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae477

Vancouver

Wang HH, Lin SH, Hung SY, Chiou YY, Hsu WC, Chang CM, et al. Renal Protective Effect of Metformin in Type 2 Diabetes Patients. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae477

BibTeX
@article{Wang2025,
  author = {Wang, Hsi-Hao and Lin, Sheng-Hsiang and Hung, Shih-Yuan and Chiou, Yuan-Yow and Hsu, Wan-Chia and Chang, Chih-Min and Liou, Hung-Hsiang and Chang, Min-Yu and Ho, Li-Chun and Wu, Ching-Fang and Lee, Yi-Che},
  title = {Renal Protective Effect of Metformin in Type 2 Diabetes Patients},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae477}
}
Kostenlos starten →